Article Text

Download PDFPDF
General and Risk Management, Patient Safety (including: medication errors, quality control)
Prevalence and spectrum of chronic kidney disease in HIV-positive patients
  1. S. Belda Rustarazo,
  2. S. Ruiz Fuente,
  3. S. Cortes de Miguel,
  4. C. Fernández López,
  5. C. Medarde Caballero,
  6. J. Cabeza Barrera,
  7. A. Valle Diaz de La Guardia
  1. 1H.U. San Cecilio, Pharmacy, Granada, Spain


Background Chronic kidney disease (CKD) is currently an important complication of HIV infection once HAART treatment has been introduced.

Purpose The aim of this study was to investigate the prevalence of CKD and patient characteristics in HIV-infected patients.

Materials and methods This was a retrospective cross-sectional study. In May 2011, using a cross-sectional method, the authors selected all HIV patients receiving antiretroviral treatment at a tertiary university hospital in Spain. The medical charts were reviewed from the moment the HAART treatment was started. Exclusion criteria included those who did not follow the treatment throughout the study period and those who were on treatment less than 6 months. The following demographic, clinical and laboratory parameters were abstracted from the clinical database: age, nadir CD4 T cell count, viral load, estimated glomerular filtration rates (GFR), hepatitis B and C co-infection, medicines, hypertension, diabetes mellitus and other co-morbidities. GFR was ascertained according to the Modification of Diet in Renal Disease (MDRD-4) criteria. CKD was defined as GFR<60 ml/min for at least 3 months.

Results During the study period 149 patients needed antiretroviral treatment at the HIV consulting service. CKD prevalence was 7.38% (11 patients). The patients' characteristics were:

Conclusions The prevalence of CKD among HIV-infected patients was higher than expected and reported by other authors. The only factors analysed that appeared to affect the presence of CKD were co-infection with HCV and exposure to lamivudine. Consequently, patients in treatment with lamivudine must be monitored and dose adjustments made. In our study, the exposure to TFV seems not to affect the prevalence. In spite of that it should be used cautiously because of its known nephrotoxicity.

GRP031 Table 1

Patients' characteristics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.